Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study

Psychiatry Research - Neuroimaging

Volumn 182, Issue 2, 2010, Pages 180-182

  Wood, Stephen J ^a   Cocchi, Luca ^a   Proffitt, Tina Marie ^a   McConchie, Mirabel ^a   Jackson, Graeme D ^b   Takahashi, Tsutomu ^a,c   Pantelis, Christos ^a   McGorry, Patrick D ^a   Berger, Gregor E ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF TOYAMA   (Japan)

^d Japan Science and Technology Corporation ^*  (Switzerland)

Author keywords

Hippocampus; MRI; Neuroprotection; Schizophrenia

Indexed keywords

ICOSAPENTAENOIC ACID ETHYL ESTER; PLACEBO;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HIPPOCAMPUS; HUMAN; MALE; NEGATIVE SYNDROME; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAXATION TIME; TREATMENT RESPONSE;

ADOLESCENT; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; PSYCHOTIC DISORDERS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 77952673349     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2009.12.003     Document Type: Article

References (15)

1. Amminger P.G., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry 2010, 67:146-154.
2. Barnes D., Harvey I., McDonald W.I., Ron M.A., Moore S. The effect of chlorpromazine and methylprednisolone on NMR relaxation times in the normal cat brain. Magnetic Resonance in Medicine 1991, 18:232-236.
3. Bazan N.G. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Molecular Neurobiology 2005, 32:89-103.
4. Bazan N.G., Rodriguez de Turco E.B., Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. Journal of Neurotrauma 1995, 12:791-814.
5. Berger G.E., Wood S., McGorry P.D. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacology Bulletin 2003, 37:79-101.
6. Berger G.E., Proffitt T.M., McConchie M., Yuen H., Wood S.J., Amminger G.P., Brewer W., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2007, 68:1867-1875.
7. Berger G.E., Wood S.J., Wellard R.M., Proffitt T.M., McConchie M., Amminger G.P., Jackson G.D., Velakoulis D., Pantelis C., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008, 33:2467-2473.
8. Frangou S., Lewis M., Wollard J., Simmons A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. Journal of Psychopharmacology 2007, 21:435-439.
9. Hirashima F., Parow A.M., Stoll A.L., Demopulos C.M., Damico K.E., Rohan M.L., Eskesen J.G., Zuo C.S., Cohen B.M., Renshaw P.F. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. American Journal of Psychiatry 2004, 161:1922-1924.
10. Lonergan P.E., Martin D.S., Horrobin D.F., Lynch M.A. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. Journal of Biological Chemistry 2002, 277:20804-20811.
11. Neema M., Goldberg-Zimring D., Guss Z.D., Healy B.C., Guttmann C.R., Houtchens M.K., Weiner H.L., Horsfield M.A., Hackney D.B., Alsop D.C., Bakshi R. 3T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis. Neuroimage 2009, 46:633-641.
12. Tappia P.S., Ladha S., Clark D.C., Grimble R.F. The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets. Molecular and Cellular Biochemistry 1997, 166:135-143.
13. Van Paesschen W., Revesz T., Duncan J.S., King M.D., Connelly A. Quantitative neuropathology and quantitative magnetic resonance imaging of the hippocampus in temporal lobe epilepsy. Annals of Neurology 1997, 42:756-766.
14. Wood S.J., Yucel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Annals of the Academy of Medicine, Singapore 2009, 38(5):396-401.
15. Yao J.K., Magan S., Sonel A.F., Gurklis J.A., Sanders R., Reddy R.D. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukotrienes and Essential Fatty Acids 2004, 71:171-176.